Skip to main content
SpringerLink
Log in

Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia

  • Original Paper
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Background

Mutations in splicing factor (SF) genes are frequently detected in myelodysplastic syndrome, but their clinical and prognostic relevance in acute myeloid leukemia (AML) have rarely been reported.

Methods

A total of 368 newly diagnosed non-M3 AML patients were included in this study. Next generation sequencing including four SF genes was performed on the genomicDNA. The clinical features and survival were analyzed using statistical analysis.

Results

We found that 64 of 368 patients harbored SF mutations. The SF mutations were much more frequently found in older or male patients. SRSF2 mutations were shown obviously co-existed with IDH2 mutation. The level of measurable residual disease after first chemotherapy was higher in SF-mutated patients compared to that in SF-wild patients, while the complete remission rate was significantly decreased. And the overall survival of SF-mutated patients was shorter than that of SF-wild patients. Moreover, our multivariable analysis suggests that the index of male, Kit mutation or ZRSR2 mutation was the independent risk factor for overall survival. SRSF2mut was associated with older age, higher proportion of peripheral blasts or abnormal cell proportion by flow cytometry.

Conclusion

SF mutation is a distinct subgroup of AML frequently associated with clinic-biological features and poor outcome. SRSF2mut could be potential targets for novel treatment in AML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The data that support the findings of this study are not openly available due to reasons of human data and are available from the corresponding author upon reasonable request.

References

  1. Ochi Y, Ogawa S (2021) Chromatin-spliceosome mutations in acute myeloid leukemia. Cancers 13(6):1232. https://doi.org/10.3390/cancers13061232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, Zang ZJ, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ding LW, Alpermann T, Sun QY, Lin DC, Chien W, Madan V, Liu LZ, Tan KT et al (2015) Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood 126(22):2491–2501. https://doi.org/10.1182/blood-2015-05-646240

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cornelissen JJ, Blaise D (2016) Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127(1):62–70. https://doi.org/10.1182/blood-2015-07-604546

    Article  CAS  PubMed  Google Scholar 

  4. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-733196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O’Meara S, Raine K, Jones DR, Teague JW et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209–2221. https://doi.org/10.1056/NEJMoa1516192

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Smith MA, Choudhary GS, Pellagatti A, Choi K, Bolanos LC, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V, Kim S, Steidl U, Walter M, Fraser I, Kulkarni A, Salomonis N, Komurov K, Boultwood J, Verma A, Starczynowski DT (2019) U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol 21(5):640–650. https://doi.org/10.1038/s41556-019-0314-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Ishiyama K, Mori H et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478(7367):64–69. https://doi.org/10.1038/nature10496

    Article  CAS  PubMed  Google Scholar 

  8. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE et al (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365(15):1384–1395. https://doi.org/10.1056/NEJMoa1103283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, Krysiak K, Harris CC, Koboldt DC, Larson DE, McLellan MD, Dooling DJ, Abbott RM, Fulton RS, Schmidt H, Kalicki-Veizer J, O’Laughlin M, Grillot M, Baty J, Heath S et al (2011) Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 44(1):53–57. https://doi.org/10.1038/ng.1031

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Shiozawa Y, Malcovati L, Gallì A, Sato-Otsubo A, Kataoka K, Sato Y, Watatani Y, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Makishima H, Shiraishi Y, Chiba K, Hellström-Lindberg E, Miyano S, Ogawa S, Cazzola M (2018) Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nat Commun 9(1):3649. https://doi.org/10.1038/s41467-018-06063-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Richardson DR, Swoboda DM, Moore DT, Johnson SM, Chan O, Galeotti J, Esparza S, Hussaini MO, Van Deventer H, Foster MC, Coombs CC, Montgomery ND, Sallman DA, Zeidner JF (2021) Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia. Am J Hematol 96(4):462–470. https://doi.org/10.1002/ajh.26110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Smeets MF, Tan SY, Xu JJ, Anande G, Unnikrishnan A, Chalk AM, Taylor SR, Pimanda JE, Wall M, Purton LE, Walkley CR (2018) Srsf2P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells. Blood 132(6):608–621. https://doi.org/10.1182/blood-2018-04-845602

    Article  CAS  PubMed  Google Scholar 

  13. Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Ali M, Neff M, Nejati J, Stehman R (2023) Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network: JNCCN 21(5):503–513. https://doi.org/10.6004/jnccn.2023.0025

    Article  CAS  PubMed  Google Scholar 

  14. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361(13):1249–1259. https://doi.org/10.1056/NEJMoa0904544

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H et al (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 117(8):2358–2365. https://doi.org/10.1182/blood-2010-03-273243

    Article  CAS  PubMed  Google Scholar 

  16. Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE, UK NCRI AML Study Group (2015) A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125(25):3878–3885. https://doi.org/10.1182/blood-2015-01-623447

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, del Bernal T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts. Blood 126(3):291–299. https://doi.org/10.1182/blood-2015-01-621664

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol: Official J Am Soc Clin Oncol 28(4):562–569. https://doi.org/10.1200/JCO.2009.23.8329

    Article  CAS  Google Scholar 

  19. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol: Official J Am Soc Clin Oncol 30(21):2670–2677. https://doi.org/10.1200/JCO.2011.38.9429

    Article  CAS  Google Scholar 

  20. Qian SX, Li JY, Tian T, Shen YF, Jiang YQ, Lu H, Wu HX, Zhang SJ, Xu W (2007) Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res 31(10):1383–1388. https://doi.org/10.1016/j.leukres.2007.02.009

    Article  CAS  PubMed  Google Scholar 

  21. Li J, Chen Y, Zhu Y, Zhou J, Xu Y, Li Y, Yu K, Pan L, Wang J, Ding J, Gu J, Zhou S, Shi J, Hong M, Xu J, Pan L, Duan L, Zhang R, Zhang S, Zhu H et al (2015) Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget 6(8):6448–6458. https://doi.org/10.18632/oncotarget.3361

    Article  PubMed  PubMed Central  Google Scholar 

  22. Yoshimi A, Lin KT, Wiseman DH, Rahman MA, Pastore A, Wang B, Lee SC, Micol JB, Zhang XJ, de Botton S, Penard-Lacronique V, Stein EM, Cho H, Miles RE, Inoue D, Albrecht TR, Somervaille T, Batta K, Amaral F, Simeoni F et al (2019) Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature 574(7777):273–277. https://doi.org/10.1038/s41586-019-1618-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Figg JW, Barajas JM, Obeng EA (2021) Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Hematol 28(2):73–79. https://doi.org/10.1097/MOH.0000000000000632

    Article  CAS  PubMed  Google Scholar 

  24. Nagata Y, Maciejewski JP (2019) The functional mechanisms of mutations in myelodysplastic syndrome. Leukemia 33(12):2779–2794. https://doi.org/10.1038/s41375-019-0617-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hou HA, Liu CY, Kuo YY, Chou WC, Tsai CH, Lin CC, Lin LI, Tseng MH, Chiang YC, Liu MC, Liu CW, Tang JL, Yao M, Li CC, Huang SY, Ko BS, Hsu SC, Chen CY, Lin CT, Wu SJ et al (2016) Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia. Oncotarget 7(8):9084–9101. https://doi.org/10.18632/oncotarget.7000

    Article  PubMed  PubMed Central  Google Scholar 

  26. Hamilton BK, Visconte V, Jia X, Tabarroki A, Makishima H, Hasrouni E, Abounader D, Kalaycio M, Sekeres MA, Sobecks R, Liu D, Bolwell H, Maciejewski B, Copelan JP, E., Tiu RV (2016) Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. Am J Hematol 91(4):406–409. https://doi.org/10.1002/ajh.24306

    Article  CAS  PubMed  Google Scholar 

  27. Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM et al (2021) Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173–2183. https://doi.org/10.1182/bloodadvances.2020004173

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Grimm J, Jentzsch M, Bill M, Backhaus D, Brauer D, Küpper J, Schulz J, Franke GN, Vucinic V, Niederwieser D, Platzbecker U, Schwind S (2021) Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation. Am J Hematol 96(10):1287–1294. https://doi.org/10.1002/ajh.26298

    Article  CAS  PubMed  Google Scholar 

  29. Wang H, Zhang N, Wu X, Zheng X, Ling Y, Gong Y (2019) Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis. Ann Hematol 98(12):2629–2639. https://doi.org/10.1007/s00277-019-03843-3

    Article  CAS  PubMed  Google Scholar 

  30. van der Werf I, Wojtuszkiewicz A, Meggendorfer M, Hutter S, Baer C, Heymans M, Valk P, Kern W, Haferlach C, Janssen J, Ossenkoppele GJ, Cloos J, Haferlach T (2021) Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification. Blood Adv 5(17):3254–3265. https://doi.org/10.1182/bloodadvances.2021004556

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hong JY, Seo JY, Kim SH, Jung HA, Park S, Kim K, Jung CW, Kim JS, Park JS, Kim HJ, Jang JH (2015) Mutations in the spliceosomal machinery genes SRSF2, U2AF1, and ZRSR2 and response to decitabine in myelodysplastic syndrome. Anticancer Res 35(5):3081–3089

    CAS  PubMed  Google Scholar 

  32. Kang MG, Kim HR, Seo BY, Lee JH, Choi SY, Kim SH, Shin JH, Suh SP, Ahn JS, Shin MG (2015) The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts. BMC Cancer 15:484. https://doi.org/10.1186/s12885-015-1493-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Saygin C, Hirsch C, Przychodzen B, Sekeres MA, Hamilton BK, Kalaycio M, Carraway HE, Gerds AT, Mukherjee S, Nazha A, Sobecks R, Goebel C, Abounader D, Maciejewski JP, Advani AS (2018) Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer J 8(1):4. https://doi.org/10.1038/s41408-017-0040-9

    Article  PubMed  PubMed Central  Google Scholar 

  34. Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F et al (2016) Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. Oncotarget 7(35):57021–57035. https://doi.org/10.18632/oncotarget.10937

    Article  PubMed  PubMed Central  Google Scholar 

  35. Wu M, Guo ZW, Huang GN, Ye YB (2021) Features and impacts on the prognosis of gene mutations in patients with acute myeloid leukemia. Neoplasma 68(5):1072–1078. https://doi.org/10.4149/neo_2021_201230N1426

    Article  CAS  PubMed  Google Scholar 

  36. Kon A, Yamazaki S, Nannya Y, Kataoka K, Ota Y, Nakagawa MM, Yoshida K, Shiozawa Y, Morita M, Yoshizato T, Sanada M, Nakayama M, Koseki H, Nakauchi H, Ogawa S (2018) Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood 131(6):621–635. https://doi.org/10.1182/blood-2017-01-762393

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, Krivtsov A, Armstrong SA, Palacino J, Buonamici S, Smith PG et al (2016) Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med 22(6):672–678. https://doi.org/10.1038/nm.4097

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from National Natural Science Foundation of China (No. 32241005 and No. 81873439).

Author information

Author notes

  1. Wenbo Jia and Xiaodong Guo contributed equally.

Authors and Affiliations

  1. Department of Hematology, Qilu Hospital of Shandong University, Shandong, 250012, Jinan, People’s Republic of China

    Wenbo Jia, Xiaodong Guo, Yihong Wei, Jinting Liu, Can Can, Ruiqing Wang, Xinyu Yang, Chunyan Ji & Daoxin Ma

Authors
  1. Wenbo Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaodong Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yihong Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jinting Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Can Can
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ruiqing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xinyu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chunyan Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daoxin Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DM designed and funded the research. CJ helped design the research. WJ and XG performed the research and wrote the manuscript. YW, JL and CC assisted with the research. RW and XY analyzed the data.

Corresponding author

Correspondence to Daoxin Ma.

Ethics declarations

Conflict of interest

The authors declare no competing financial interests.

Ethics approval and consent

All samples were collected after informed consent.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 132.3 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jia, W., Guo, X., Wei, Y. et al. Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia. Mol Biol Rep 50, 6601–6610 (2023). https://doi.org/10.1007/s11033-023-08597-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-023-08597-w

Keywords

Search

Navigation